Advertisement
Advertisement
U.S. Markets open in 4 hrs 44 mins
Advertisement
Advertisement
Advertisement
Advertisement

Lexaria Bioscience Corp. (LEXX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.3000-0.2200 (-4.87%)
At close: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.5200
Open4.3400
Bid4.0600 x 1200
Ask4.5200 x 2900
Day's Range4.2000 - 4.4626
52 Week Range3.7790 - 12.5000
Volume136,468
Avg. Volume317,744
Market Cap25.589M
Beta (5Y Monthly)1.94
PE Ratio (TTM)N/A
EPS (TTM)-0.9170
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.75
  • GlobeNewswire

    IBN (InvestorBrandNetwork) Announces EDGE Podcast Interview with Lexaria Bioscience Corp. CEO Chris Bunka

    NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted financial news and publishing company for private and public entities, today announces that Chris Bunka, Chairman and CEO of Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently appeared on the EDGE Podcast, a series focused on providing the business owner's playbook about the inner game of building a successful business and giving listeners the e

  • ACCESSWIRE

    Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2

    "Cannabinoids have the potential to prevent as well as treat infection by SARS-CoV-2"KELOWNA, BC / ACCESSWIRE / January 18, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, comments on an independent January 10 study, available here, that discovered that "Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants".

  • ACCESSWIRE

    Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4

    • Dosing is expected to begin by April, 2022KELOWNA, BC / ACCESSWIRE / December 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to report that Independent Review Board ("IRB") approval has been received ahead of schedule for its upcoming DehydraTECH-CBD human hypertension study HYPER-H21-4.

Advertisement
Advertisement